TESARO Company Profile (NASDAQ:TSRO)

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

TESARO, Inc. (NASDAQ:TSRO) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($2.55) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.26) by $0.29. The firm earned $3.10 million during the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The business's revenue was up 909.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.22) earnings per share. View TESARO's Earnings History.

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for TESARO.

21 brokers have issued 1 year price objectives for TESARO's stock. Their forecasts range from $94.00 to $236.00. On average, they expect TESARO's share price to reach $173.52 in the next year. View Analyst Ratings for TESARO.

Here are some recent quotes from research analysts about TESARO stock:

• 1. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
• 2. Cann analysts commented, "On Saturday, June 3, 2017, Tesaro provided a corporate update that described initial data from the TOPACIO trial of niraparib (Zejula) plus Keytruda (pembrolizumab) and results of a phase I trial of TSR-042, and provided an update on the commercial launch of Zejula and its commercial businesses in the US and Europe. The launch is exceeding our expectations, and management reiterated plans to advance Zejula into the front-line ovarian cancer setting and to expand into other tumor types, including non-small cell lung cancer. We are adjusting our Zejula outlook based on the current status of the launch." (6/5/2017)
• 3. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
• 4. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (3/31/2017)
• 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Some companies that are related to TESARO include Exelixis (EXEL), BIOVERATIV INC (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), Prothena Corporation PLC (PRTA), Axovant Sciences Ltd (AXON), Sarepta Therapeutics (SRPT), AveXis (AVXS) and Spark Therapeutics (ONCE).

TESARO's management team includes the folowing people:

• David M. Mott, Independent Chairman of the Board
• Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
• Leon O. Moulder Jr., Chief Executive Officer, Director
• Timothy R. Pearson, Chief Financial Officer, Executive Vice President
• Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
• Grant C. Bogle, Senior Vice President, Chief Commercial Officer
• Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
• Lawrence M. Alleva, Independent Director
• James O. Armitage M.D., Independent Director

TESARO's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include InterWest Venture Management Co (3.75%), Peregrine Capital Management LLC (0.18%), Creative Planning (0.06%), Whittier Trust Co. (0.02%), Jag Capital Management LLC (0.02%) and Capital Impact Advisors LLC (0.02%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Institutional Ownership Trends for TESARO.

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Jag Capital Management LLC, Peregrine Capital Management LLC, Capital Impact Advisors LLC and CenturyLink Investment Management Co. Company insiders that have sold TESARO stock in the last year include Edward C English, Grant C Bogle, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Insider Buying and Selling for TESARO.

TESARO's stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, Oregon Public Employees Retirement Fund, Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Xact Kapitalforvaltning AB, Capstone Asset Management Co., Private Capital Advisors Inc. and Fox Run Management L.L.C.. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky, Enterprise Associates 13 L New and James O Armitage. View Insider Buying and Selling for TESARO.

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TESARO stock can currently be purchased for approximately $129.87.